13/11/2017
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Quarterly / Interim Statement/9-month figures NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN. SHOP APOTHEKE EUROPE increases consolidated revenues by 53% and confirms raised guidance.
As a result of the successful growth initiatives, the number of active customers rose significantly by around 50% from 1.6m as of 30 September 2016 to almost 2.4m. SHOP APOTHEKE EUROPE processed 4.2m orders during the reporting period. This corresponds to an increase of 50% (2016: 2.8m) against the same period last year. In the third quarter, around 76% of orders were placed by existing customers, an increase of three percentage points compared to the already high level in the same period last year (73%). The share of mobile website visits increased again to 53% in the third quarter of 2017, up from 44% in the same quarter of the previous year. At Group level, SHOP APOTHEKE EUROPE increased its gross profit in the period under review from EUR 25.6m in the previous year's period to EUR 40.6m - an increase of nearly 59%. In connection with the next automation step in logistics, changes in the incoming goods system led to a temporary increase in volumes being purchased from wholesalers in the third quarter. This transitionally necessary measure and the planned increase in expenses for acquiring new customers had an impact on third quarter's earnings. Nevertheless, the gross margin at Group level improved by 0.7 percentage points to 21.2% in the nine-month period. In administration, SHOP APOTHEKE EUROPE benefited from economies of scale during the reporting period: administrative expenses (before depreciation) amounted to EUR 5.8m in the first nine months of 2017 (prior year period: EUR 5.1m). Relative to sales, administrative expenses decreased to 3.1% (previous year: 4.1% or 3.8% adjusted for one-off IPO costs). In the period under review, this led to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR -6.8m after EUR -4.8m in the previous year and EUR -4.3m adjusted for one-off expenses. After depreciation and amortization of EUR 4.1m (previous year: EUR 2.3m), earnings before interest and taxes (EBIT) amounted to EUR -11.0m (previous year: EUR -7.1m or EUR -6.6m adjusted). Market position in the core market of Germany further expanded through profitable growth International business remains growth driver Germany Services segment grows with the Group's increasing business volume Acquisition of Europa Apotheek successfully completed, guidance confirmed ABOUT SHOP APOTHEKE EUROPE. SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to more than 2.4 m active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services. SHOP APOTHEKE EUROPE generated sales of about EUR 191 m in the first nine months of 2017 and growth of +53% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016. MEDIA CONTACTS. Trade and public media: Financial media: Investor Relations:
Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.
13.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | SHOP APOTHEKE EUROPE N.V. |
Dirk Hartogweg 14 | |
5928 LV Venlo | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | ulrich.wandel@shop-apotheke.com |
Internet: | www.shop-apotheke-europe.com |
ISIN: | NL0012044747 |
WKN: | A2AR94 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |